GO
Loading...

Medicine

More

  • April 2- Bill Gates, the World Bank and other donors are stepping up efforts to fight neglected tropical diseases in Africa and other low-income regions with a $240 million injection of new funding. The new collaboration includes $50 million from the Bill& Melinda Gates Foundation and $50 million from the Children's Investment Fund Foundation.

  • MannKind shares soar as diabetes drug gets nod Wednesday, 2 Apr 2014 | 8:10 AM ET
    MannKind's David Thomson

    U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

  • FDA advisers back MannKind's inhaled diabetes drug Tuesday, 1 Apr 2014 | 5:47 PM ET

    U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.`

  • HYATTSVILLE, Md., April 1- Mannkind Corp's inhaled diabetes drug Afrezza is safe and effective for diabetes patients with either the type 1 or type 2 form of the disease, U.S. health advisers said on Tuesday in recommending its approval for sales in the United States.

  • March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.

  • WASHINGTON, March 31- Bariatric weight loss surgery on obese patients with type 2 diabetes helped many to get their blood sugar to healthy levels and to no longer require any diabetes medicines, including insulin, three years after the procedure, according to data presented at a major medical meeting on Monday.

  • WASHINGTON, March 31- Bariatric weight loss surgery on obese patients with type 2 diabetes helped many to get their blood sugar to healthy levels and to no longer require any diabetes medicines, including insulin, three years after the procedure, according to data presented at a major medical meeting on Monday.

  • FDA allows Curis to resume testing cancer drug Monday, 31 Mar 2014 | 7:44 AM ET

    March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. The company's shares jumped about 22 percent to $3.35 in trading before the bell. The Lexington, Massachusetts- based company's shares closed at $2.75 on the Nasdaq on Friday.

  • Prana says drug fails Alzheimer's disease study Monday, 31 Mar 2014 | 6:26 AM ET

    March 31- Prana Biotechnology Ltd said its experimental drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage study in patients with a mild form of the condition. The company's shares fell about 38 percent to $6.13 in premarket trade on Monday.

  • *Novartis to seek approval with global regulators. ZURICH, March 31- Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine.

  • ZURICH, March 31- Swiss drugmaker Novartis is set to end a late-stage clinical trial of a chronic heart failure drug early, following strong interim results. Novartis said it would start talks with global health regulators about filing for drug for approval.

  • Nonsurgical fix could replace open-heart surgery Sunday, 30 Mar 2014 | 2:07 PM ET
    Medtronic's CoreValve Evolut

    A new study boosts fixing a bad aortic valve, the heart's main gate, without open-heart surgery.

  • WASHINGTON, March 30- A new type of heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said.

  • WASHINGTON, March 30- An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday.

  • March 29- Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

  • March 28- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. It affects about 4,000 people in the United States and 25,000 worldwide.

  • Biotech funds: Only for those immune to fear Friday, 28 Mar 2014 | 1:53 PM ET

    Biotech has been so hot the past two years that the sector is starting to raise red flags.

  • March 28- Idera Pharmaceuticals Inc said its lead experimental drug for the most common form of psoriasis was found to be safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial.

  • March 28- Idera Pharmaceuticals Inc said its lead experimental drug for the most common form of psoriasis was found to be safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial. The company's shares rose 40 percent to $5.40 in premarket trading on Friday.

Most Popular Video

Monday, 21 Apr 2014 | 12:02 AM ET

Simon Grose-hodge, Head of Investment Advisory, South Asia at LGT Bank Singapore, remains overweight on developed markets as the U.S. and Europe are showing signs of recovery.

Sunday, 20 Apr 2014 | 9:42 PM ET

Caroline Russell, CEO of Boh Plantations, speaks to CNBC's Julia Wood about the company's focus on maintaining dominance in its home market of Malaysia.

Sunday, 20 Apr 2014 | 8:47 PM ET

As the Beijing Auto Show kicks off on Monday, Martin Winterkorn, Chairman and CEO at Volkswagen, says plug-in hybrids will dominate its lineup in China for alternative energy cars.